Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity Flow Analysis
1.6.2. Bottom-up Approach
1.7. List of Secondary Sources
1.8. List of Abbreviations
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. The Rise of E-Commerce
3.2.1.2. Growing Demand for Outsourcing Services
3.2.1.3. Rising Demand for Cold Chain Logistics
3.2.1.4. Growing Applications of Reverse Logistics in Biopharmaceutical Industry
3.2.2. Market Restraint Analysis
3.2.2.1. High Operational Costs
3.2.2.2. Compliance Issues While Outsourcing
3.3. Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market: Product Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market; Product Type Movement Analysis
4.3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Product Type, 2018 to 2030 (USD Million)
4.4. Branded
4.4.1. Branded market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Generic
4.5.1. Generic market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Biosimilar
4.6.1. Biosimilar market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Vaccine
4.7.1. Vaccine market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Cell Therapy
4.8.1. Cell therapy market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Gene Therapy
4.9.1. Gene therapy market estimates and forecasts 2018 to 2030 (USD Million)
4.10. Others
4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market: Temperature Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market; Temperature Movement Analysis
5.3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Temperature, 2018 to 2030 (USD Million)
5.4. Ambient
5.4.1. Ambient market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Refrigerated
5.5.1. Refrigerated market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Frozen
5.6.1. Frozen market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Ultra-frozen/Deep-Frozen
5.7.1. Ultra-frozen/Deep-Frozen market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Cryogenic
5.8.1. Cryogenic market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market: Therapeutic Area Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market; Therapeutic Area Movement Analysis
6.3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
6.4. Oncology
6.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Cardiovascular Diseases
6.5.1. Cardiovascular diseases market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Infectious Diseases
6.6.1. Infectious diseases market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Neurology
6.7.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
6.8. Diabetes
6.8.1. Diabetes market estimates and forecasts 2018 to 2030 (USD Million)
6.9. Nephrology
6.9.1. Nephrology market estimates and forecasts 2018 to 2030 (USD Million)
6.10. Rheumatology
6.10.1. Rheumatology market estimates and forecasts 2018 to 2030 (USD Million)
6.11. Allergy/Asthma
6.11.1. Allergy/Asthma market estimates and forecasts 2018 to 2030 (USD Million)
6.12. Gastroenterology
6.12.1. Gastroenterology market estimates and forecasts 2018 to 2030 (USD Million)
6.13. Ophthalmology
6.13.1. Ophthalmology market estimates and forecasts 2018 to 2030 (USD Million)
6.14. Others
6.14.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market: Manufacturer Size Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market; Manufacturer Size Movement Analysis
7.3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Manufacturer Size, 2018 to 2030 (USD Million)
7.4. Large
7.4.1. Large market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Medium
7.5.1. Medium market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Small
7.6.1. Small market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market: Service Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market; Service Movement Analysis
8.3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
8.4. Storage and Shipping
8.4.1. Storage and Shipping market estimates and forecasts 2018 to 2030 (USD Million)
8.5. Order-to-cash
8.5.1. Order-to-cash market estimates and forecasts 2018 to 2030 (USD Million)
8.6. Title Model
8.6.1. Title Model market estimates and forecasts 2018 to 2030 (USD Million)
8.7. DSCSA and Serialization Services
8.7.1. DSCSA and Serialization Services market estimates and forecasts 2018 to 2030 (USD Million)
8.8. Pharmaceutical Sampling
8.8.1. Pharmaceutical Sampling market estimates and forecasts 2018 to 2030 (USD Million)
8.9. Others
8.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Company Market Position Analysis, 2024
9.3. Company Profiles
9.3.1. CEVA Logistics
9.3.1.1. Company overview
9.3.1.2. Financial performance
9.3.1.3. Service benchmarking
9.3.1.4. Strategic initiatives
9.3.2. Cencora Corporation (ICS)
9.3.2.1. Company overview
9.3.2.2. Financial performance
9.3.2.3. Service benchmarking
9.3.2.4. Strategic initiatives
9.3.3. DB SCHENKER
9.3.3.1. Company overview
9.3.3.2. Financial performance
9.3.3.3. Service benchmarking
9.3.3.4. Strategic initiatives
9.3.4. Kuehne+Nagel
9.3.4.1. Company overview
9.3.4.2. Financial performance
9.3.4.3. Service benchmarking
9.3.4.4. Strategic initiatives
9.3.5. Kerry Logistics Network Limited
9.3.5.1. Company overview
9.3.5.2. Financial performance
9.3.5.3. Service benchmarking
9.3.5.4. Strategic initiatives
9.3.6. Cardinal Health
9.3.6.1. Company overview
9.3.6.2. Financial performance
9.3.6.3. Service benchmarking
9.3.6.4. Strategic initiatives
9.3.7. McKesson Corporation
9.3.7.1. Company overview
9.3.7.2. Financial performance
9.3.7.3. Service benchmarking
9.3.7.4. Strategic initiatives
9.3.8. EVERSANA.
9.3.8.1. Company overview
9.3.8.2. Financial performance
9.3.8.3. Service benchmarking
9.3.8.4. Strategic initiatives
9.3.9. Thermo Fisher Scientific Inc.
9.3.9.1. Company overview
9.3.9.2. Financial performance
9.3.9.3. Service benchmarking
9.3.9.4. Strategic initiatives
9.3.10. Knipper Health
9.3.10.1. Company overview
9.3.10.2. Financial performance
9.3.10.3. Service benchmarking
9.3.10.4. Strategic initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, by Product Type, 2018 - 2030 (USD Million)
Table 4 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, by Temperature, 2018 - 2030 (USD Million)
Table 5 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 6 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, by Manufacturer Size, 2018 - 2030 (USD Million)
Table 7 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, by Service, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 Pharmaceutical Third-Party Logistics (3PL) Services, Market Segmentation
Fig. 7 Market Driver Analysis (Current & Future Impact)
Fig. 8 Market Restraint Analysis (Current & Future Impact)
Fig. 9 Porter’s Five Forces Analysis
Fig. 10 PESTEL Analysis
Fig. 11 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Branded, 2018 - 2030 (USD Million)
Fig. 12 U.S Pharmaceutical Third-Party Logistics (3PL) Services, for Generic, 2018 - 2030 (USD Million)
Fig. 13 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Biosimilar, 2018 - 2030 (USD Million)
Fig. 14 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Vaccine, 2018 - 2030 (USD Million)
Fig. 15 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Cell Therapy, 2018 - 2030 (USD Million)
Fig. 16 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Gene Therapy, 2018 - 2030 (USD Million)
Fig. 17 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Others, 2018 - 2030 (USD Million)
Fig. 18 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Ambient, 2018 - 2030 (USD Million)
Fig. 19 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Refrigerated, 2018 - 2030 (USD Million)
Fig. 20 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Frozen, 2018 - 2030 (USD Million)
Fig. 21 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Ultra-frozen/Deep-Frozen, 2018 - 2030 (USD Million)
Fig. 22 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Cryogenic, 2018 - 2030 (USD Million)
Fig. 23 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Oncology, 2018 - 2030 (USD Million)
Fig. 24 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for cardiovascular diseases, 2018 - 2030 (USD Million)
Fig. 25 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Infectious Diseases, 2018 - 2030 (USD Million)
Fig. 26 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Neurology, 2018 - 2030 (USD Million)
Fig. 27 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Diabetes, 2018 - 2030 (USD Million)
Fig. 28 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Nephrology, 2018 - 2030 (USD Million)
Fig. 29 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Rheumatology, 2018 - 2030 (USD Million)
Fig. 30 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Allergy/Asthma, 2018 - 2030 (USD Million)
Fig. 31 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Gastroenterology, 2018 - 2030 (USD Million)
Fig. 32 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Ophthalmology, 2018 - 2030 (USD Million)
Fig. 33 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Others, 2018 - 2030 (USD Million)
Fig. 34 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Large, 2018 - 2030 (USD Million)
Fig. 35 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Medium, 2018 - 2030 (USD Million)
Fig. 36 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Small, 2018 - 2030 (USD Million)
Fig. 37 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Storage and Shipping, 2018 - 2030 (USD Million)
Fig. 38 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Order-to-cash, 2018 - 2030 (USD Million)
Fig. 39 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Title Model, 2018 - 2030 (USD Million)
Fig. 40 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for DSCSA and Serialization Services, 2018 - 2030 (USD Million)
Fig. 41 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Pharmaceutical Sampling, 2018 - 2030 (USD Million)
Fig. 42 U.S. Pharmaceutical Third-Party Logistics (3PL) Services, for Others, 2018 - 2030 (USD Million)